Ipilimumab in melanoma

摘要: Ipilimumab is a fully human monoclonal antibody directed against the cytotoxic T-lymphocyte antigen-4 receptor. Blocking signaling has been shown to enhance T-cell activation and amplify T-cell-mediated immunity. Ipilimumab, either as single agent or in combination with gp100 vaccination, significantly prolonged overall survival randomized Phase III trial patients disease progression after prior treatment when compared alone. In previously untreated patients, addition of ipilimumab dacarbazine also survival. The most common adverse events are immune related. Adherence established algorithms immune-related advocated. Predictive factors for activity have not identified but would be great value selection who likely benefit from this innovative immunotherapy. Outstanding issues include role ipilimuma...